©2024 Stanford Medicine
The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
Recruiting
I'm InterestedTrial ID: NCT03552705,
Purpose
Patients who tear their ACL are at high risk for developing arthritis (post-traumatic
osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to
deterioration of joint health. This study will determine whether treatment with Tranexamic
Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and
reconstructive surgery reduces inflammation and improves joint health as a new strategy to
prevent or delay the onset of PTOA.
Official Title
Novel Strategies to Combat Post-Traumatic Osteoarthritis (PTOA):The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
Stanford Investigator(s)
Constance Chu, MD
Professor of Orthopaedic Surgery (Sports Medicine)
Eligibility
Inclusion Criteria:
- age 18-30 years
- within 4 days of unilateral ACL injury
- presence of effusion/hemarthrosis.
Exclusion Criteria:
- inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/
pseudogout
- systemic or acute illness requiring medications
- concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
- prior surgery to either knee
- prior injury to either knee requiring crutches
- history of thromboembolic disease
- current use of combination hormonal contraception
- chronic NSAID use
- cortisone injection to either knee within the prior 3 months
- not indicated for or unable to undergo ACLR within 3 months of injury
Intervention(s):
drug: Tranexamic Acid
drug: Placebos
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christine Hoang
650-721-7612